131 related articles for article (PubMed ID: 10647508)
1. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.
Fokkema E; de Vries EG; Meijer S; Groen HJ
Cancer Chemother Pharmacol; 2000; 45(1):89-92. PubMed ID: 10647508
[TBL] [Abstract][Full Text] [Related]
2. Acute and cumulative effects of carboplatin on renal function.
Sleijfer DT; Smit EF; Meijer S; Mulder NH; Postmus PE
Br J Cancer; 1989 Jul; 60(1):116-20. PubMed ID: 2679841
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.
Fokkema E; Groen HJ; Bauer J; Uges DR; Weil C; Smith IE
J Clin Oncol; 1999 Dec; 17(12):3822-7. PubMed ID: 10577855
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.
Sessa C; Minoia C; Ronchi A; Zucchetti M; Bauer J; Borner M; de Jong J; Pagani O; Renard J; Weil C; D'Incalci M
Ann Oncol; 1998 Dec; 9(12):1315-22. PubMed ID: 9932162
[TBL] [Abstract][Full Text] [Related]
7. Effects of gemcitabine on renal function in patients with non-small cell lung cancer.
Gietema JA; Groen HJ; Meijer S; Smit EF
Eur J Cancer; 1998 Jan; 34(1):199-202. PubMed ID: 9624259
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity of 1,1-diaminomethylcyclohexane sulphato platinum II (spiroplatin; TNO-6).
Offerman JJ; Meijer S; Mulder NH; Sleijfer DT; Bijster P; Hellendoorn HB; Donker AJ; van der Hem GK
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):447-51. PubMed ID: 3891361
[TBL] [Abstract][Full Text] [Related]
10. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer].
Furuse K; Fukuoka M; Kurita Y; Ariyoshi Y; Niitani H; Yoneda S; Fujii M; Hasegawa K; Nishiwaki Y; Tamura M
Gan To Kagaku Ryoho; 1992 Jun; 19(6):879-84. PubMed ID: 1318698
[TBL] [Abstract][Full Text] [Related]
11. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
[TBL] [Abstract][Full Text] [Related]
13. The effect of fenoldopam on renal haemodynamics and natriuresis in chronic renal failure.
de Fijter CW; Comans EF; de Vries PM; Oe PL; Roos JC; Smit AJ; Streurman O; Donker AJ
Neth J Med; 1990 Jun; 36(5-6):267-78. PubMed ID: 1975651
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of oral JM216 given twice daily.
Beale P; Raynaud F; Hanwell J; Berry C; Moore S; Odell D; Judson I
Cancer Chemother Pharmacol; 1998; 42(2):142-8. PubMed ID: 9654114
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of oral topotecan in advanced non-small cell lung cancer.
White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
[TBL] [Abstract][Full Text] [Related]
16. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest.
George CM; Haraf DJ; Mauer AM; Krauss SA; Hoffman PC; Rudin CM; Szeto L; Vokes EE
Invest New Drugs; 2001; 19(4):303-10. PubMed ID: 11561689
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation.
Judson I; Cerny T; Epelbaum R; Dunlop D; Smyth J; Schaefer B; Roelvink M; Kaplan S; Hanauske A
Ann Oncol; 1997 Jun; 8(6):604-6. PubMed ID: 9261531
[TBL] [Abstract][Full Text] [Related]
19. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
20. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
